Sakar Healthcare

Sakar Healthcare EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sakar Healthcare (SAKAR.NS) as of Nov 5, 2026 is 453.24 M INR. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 496.83 M INR — a change of -8.77% (lower).

EBITDA

453.24 MINR

YoY

-8.77%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sakar Healthcare is 2026 453.24 M INR. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sakar Healthcare was 2025 496.83 M INR. It decreases by -8.77% lower compared to the previous year.

The Sakar Healthcare EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2019
191.80 M INR
Jan 1, 2020
206.84 M INR
Jan 1, 2021
230.28 M INR
Jan 1, 2022
485.56 M INR
Jan 1, 2023
334.43 M INR
Jan 1, 2024
676.01 M INR
Jan 1, 2025
496.83 M INR
Jan 1, 2026
453.24 M INR
The Sakar Healthcare EBITDA history
YEAREBITDAYoY
453.24 MINR-8.77%
496.83 MINR-26.51%
676.01 MINR+102.14%
334.43 MINR-31.12%
485.56 MINR+110.85%
230.28 MINR+11.33%
206.84 MINR+7.85%
191.80 MINR+51.82%
126.33 MINR-5.21%
133.27 MINR+138.38%
55.91 MINR-29.02%
78.77 MINR+0.39%
78.47 MINR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Sakar Healthcare Stock analysis

What does Sakar Healthcare do? Sakar Healthcare Ltd. manufactures pharmaceutical products including liquid orals, cephalosporin tablets, capsules, dry powder syrups, dry powder injections, liquid injectables (SVP) in ampoules and vials, lyophilized injections, and oral solid dosages. The company operates as a contract development and manufacturing organization (CDMO) providing these products under brand names such as Oral - Liquid Syrup & Suspension, Liquid Injectable (SVP)-Vials & Ampoules, Cephalosporin - Dry Powder Injections, Cephalosporin - Oral Solid, and Lyophilised Injections (In Vials). Sakar Healthcare serves markets in 14 countries including Uganda, Kenya, Yemen, Ethiopia, Congo, Zimbabwe, Nigeria, Malawi, Philippines, Peru, Vietnam, and Cote D’Ivoire with approximately 321 product registrations. The company generates revenue through the sale of these pharmaceutical products to healthcare providers and distributors in these regions. The firm’s manufacturing unit is accredited by regulatory authorities in 14 countries, which enables it to produce and distribute products across these markets. Sakar Healthcare’s product portfolio includes liquid injectables (SVP) in ampoules and vials, dry powder injections, and oral solid dosages, which are sold to healthcare facilities and pharmacies. The company’s contracts with clients in the pharmaceutical sector involve developing and manufacturing products according to their specifications, with the firm’s focus on cephalosporin-based medications and liquid formulations. Sakar Healthcare Ltd. focuses on providing contract manufacturing services for pharmaceutical products, with a strong emphasis on cephalosporin formulations and liquid-based medications. The company’s products are registered in 321 product registrations across various countries, supporting its operations in 14 regulatory markets. Revenue is derived from the production and sale of these registered products to healthcare providers and distributors in the regions where it holds regulatory accreditation. Sakar Healthcare is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sakar Healthcare stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sakar Healthcare is 453.24 M INR in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Sakar Healthcare changed from 496.83 M INR to 453.24 M INR, representing a -8.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Sakar Healthcare since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s INR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Sakar Healthcare historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Sakar Healthcare

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Sakar Healthcare